Last reviewed · How we verify
NCT06577987
Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies
Phase 1 trial testing CID-078 Monotherapy in Advanced Solid Tumor in 220 participants. Currently enrolling.
14 January 2027
Quick facts
| Lead sponsor | Circle Pharma |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 220 |
| Start date | 14 August 2024 |
| Primary completion | 14 January 2027 |
| Estimated completion | 14 March 2027 |
| Sites | 10 locations across United States |
Drugs / interventions tested
- CID-078 Monotherapy — full drug profile →
Conditions studied
- Advanced Solid Tumor — all drugs for Advanced Solid Tumor →
- Metastatic Solid Tumor — all drugs for Metastatic Solid Tumor →
- Refractory Solid Tumor — all drugs for Refractory Solid Tumor →
- Cancer — all drugs for Cancer →
Sponsor
Circle Pharma — full company profile →
Who can join
12 and older, any sex, with Advanced Solid Tumor or Metastatic Solid Tumor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a first-in-human, multicenter, open-label, phase 1 study to evaluate safety, tolerability, and efficacy of CID-078, a Cyclin A/B-RxL inhibitor, in patients with advanced solid tumors.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting G1-S-checkpoint-compromised cancers with cyclin A/B RxL inhibitors.
Singh S, Gleason CE, Fang M, Laimon YN, et al · · 2025 · cited 11× · PMID 40836083 · DOI 10.1038/s41586-025-09433-w -
Orally Bioavailable Cyclin A/B RxL Inhibitors: Optimization of a Novel Class of Macrocyclic Peptides That Target E2F-High and G1-S-Checkpoint-Compromised Cancers.
Shapiro JA, Dupper NJ, Fraga-Walton B, Bockus AT, et al · · 2026 · PMID 41721763 · DOI 10.1021/acs.jmedchem.5c02445
Verify or expand the search:
- PubMed search for NCT06577987
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumor
Currently open trials in the same condition.
- NCT07300943 — Study in Advanced Solid Tumor Patients · Phase 1, PHASE2 · recruiting
- NCT07304128 — A Study of PLB-002 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07213830 — A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity · Phase 1, PHASE2 · recruiting
- NCT07226349 — A Study of BG-75098 Alone and in Combination With Other Agents in Adults With Advanced Solid Tumors · Phase 1 · recruiting
- NCT07222267 — An Investigational Study of BG-75202 Alone and in Combination With Other Therapeutic Agents in Adults With Advanced Soli · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06577987 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Circle Pharma
- Last refreshed: 15 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06577987.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing